- Home
- SST vs DBVT Comparison
SST vs DBVT Comparison
Compare SST & DBVT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SST
- DBVT
- Stock Information
- Founded
- SST 2013
- DBVT 2002
- Country
- SST United States
- DBVT France
- Employees
- SST 300
- DBVT N/A
- Industry
- SST Diversified Commercial Services
- DBVT Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- SST Consumer Discretionary
- DBVT Health Care
- Exchange
- SST Nasdaq
- DBVT Nasdaq
- Market Cap
- SST 83.4M
- DBVT 93.3M
- IPO Year
- SST N/A
- DBVT N/A
- Fundamental
- Price
- SST $1.20
- DBVT $0.80
- Analyst Decision
- SST Hold
- DBVT Strong Buy
- Analyst Count
- SST 1
- DBVT 2
- Target Price
- SST $2.00
- DBVT $5.00
- AVG Volume (30 Days)
- SST 380.3K
- DBVT 15.2K
- Earning Date
- SST 08-08-2024
- DBVT 10-29-2024
- Dividend Yield
- SST N/A
- DBVT N/A
- EPS Growth
- SST N/A
- DBVT N/A
- EPS
- SST N/A
- DBVT N/A
- Revenue
- SST $363,437,000.00
- DBVT $13,814,000.00
- Revenue This Year
- SST N/A
- DBVT N/A
- Revenue Next Year
- SST $15.17
- DBVT $1,258.14
- P/E Ratio
- SST N/A
- DBVT N/A
- Revenue Growth
- SST N/A
- DBVT 163.02
- 52 Week Low
- SST $1.04
- DBVT $0.50
- 52 Week High
- SST $3.02
- DBVT $3.25
- Technical
- Relative Strength Index (RSI)
- SST 44.19
- DBVT 34.18
- Support Level
- SST $1.19
- DBVT $0.85
- Resistance Level
- SST $1.28
- DBVT $0.91
- Average True Range (ATR)
- SST 0.14
- DBVT 0.07
- MACD
- SST -0.00
- DBVT -0.01
- Stochastic Oscillator
- SST 15.38
- DBVT 20.88
About SST System1 Inc.
System1 Inc develops technology and data science to operate a responsive acquisition marketing platform. It serves customers in the areas of health and wellness, automotive, finance, travel, and entertainment. The company's segment includes Owned and Operated Advertising (O&O); and Partner Network. It generates maximum revenue from the Owned and Operated Advertising (O&O) segment.
About DBVT DBV Technologies S.A.
DBV Technologies SA is a clinical-stage specialty biopharmaceutical company focused on changing the field of immunotherapy by developing a novel technology platform called Viaskin. The therapeutic approach is based on epicutaneous immunotherapy or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin, an epicutaneous patch (i.e., a skin patch). Viaskin targets specific antigen-presenting immune cells in the skin, called Langerhans cells, that capture the antigen and migrate to the lymph node to activate the immune system without passage of the antigen into the bloodstream, minimizing systemic exposure in the body. Its main product candidate is Viaskin Peanut for the treatment of peanut-allergic patients.